Brief: Shanghai Henlius Biotech Updates On Phase 3 Clinical Study Of HLX04-O
02/04/2025 16:19
April 2 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY INJECTION HLX04-O PHASE 3 CLINICAL STUDY MET PRIMARY STUDY ENDPOINT Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln